BBB-crossing ionizable upconversion nanoparticles for synergistic therapy of carbapenem-resistant central nervous system infection

Research Background

CNS infections caused by carbapenem-resistant Enterobacteriaceae (CRE) pose a critical global healthcare challenge. These infections are exceptionally difficult to treat due to two major barriers: the blood-brain barrier (BBB), which blocks most antibiotics from reaching infection sites in the brain, and the protective biofilms produced by bacteria that significantly enhance antibiotic resistance. The World Health Organization has classified CRE as a priority pathogen, underscoring the urgent need for innovative treatment strategies.

Research Significance

The study introduces an innovative solution: a novel nanoparticle system, UC@MOF@RB+MEM, capable of responding to pH changes and near-infrared light. Its significance lies in the nanoparticles’ ability to cross the BBB during inflammation, precisely target infection sites, and release antibacterial agents locally. By combining photodynamic therapy with conventional antibiotics, the system effectively disrupts biofilms, eliminates drug-resistant bacteria, and reduces neuroinflammation through the protective effects of zinc ions.

Application Prospects

The successful application of this nanotechnology in mouse models demonstrates significant potential for clinical translation. This strategy not only provides a powerful tool against CRE-related CNS infections but also establishes a versatile platform adaptable to treating other antimicrobial-resistant infections. The research team believes this innovative approach could revolutionize the treatment of challenging infections beyond the CNS, potentially impacting global antimicrobial resistance management.

Sources: https://spj.science.org/doi/10.34133/research.0946